TAIZ -Monocytes for the Induction of Donor Specific Tolerance in Renal Allograft Recipients (Cadaver Kidney)

NCT00223093 | Unknown Phase 1

• 1 other identifier: 006
• Study Type: interventional
• Target: 10
• Locations: 0 countries
• Sites: N/A

Brief Summary

Induce tolerance or reduce the amount of immunosuppression after renal transplant patient (receiving cadaver kidney)with so called TAIZ-monocytes

Conditions

Renal Transplantation

Keywords

renal transplantation, TAIZ-moncytes

Outcome Measures

Primary Outcomes (5)

• graft survival

• replacement of immunosuppressives after treatment with Transplant-Acceptance Inducing Cells (TAIC)

• serum creatinine

• rejection episodes

• re-introduction of immunosuppressives.

Secondary Outcomes (1)

• safety and tolerability of the treatment with Transplant-Acceptance Inducing Cells (TAIC) Adverse Events (AEs)

Interventions

TAIZ DRUG

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female adult patients aged between 18 and 64 years (inclusive). A female of childbearing potential may be enrolled provided she:
• has a negative pregnancy test at Screening and
• is routinely using adequate contraception prior to and during the study and
• agrees not to attempt to become pregnant during the study and
• is not lactating A female of non-childbearing potential will be defined as one who has been postmenopausal for at least one year or has been surgically sterilised.
• Patients receiving a first renal transplant.
• Patients who fulfil the criteria to receive an allogeneic renal transplant from a cadaver (according to the Eurotransplant (ET) manual on organ allocation and the Bundesärztekammer allocation criteria).
• Patients who, after the nature of the study and the disclosure of their data has been explained to them, have freely given Informed Consent in writing.

You may not qualify if:

• Patients who have received a renal transplant.
• Patients who have an active infection at the time of entry into the study (Screening).
• Recipient and donor pairs who show the following incompatible CMV constellation: the donor is CMV positive and the recipient is CMV negative.
• Patients and donor who have positive evidence of HIV or have active virus hepatitis B and C.
• Patients with a history of alcohol and/or drug abuse.
• Patients who are pregnant women or nursing mothers.
• Known hypersensitivity or contraindication to one of the immunosuppressives administered during the course of the study: tacrolimus, sirolimus or steroids (prednisolone and methylprednisolone).
• Patients with a history or present symptoms of autoimmune vasculitis.
• Detection of \>5% HLA antibodies (current values determined during the last three months).
• Patients with a malignancy or history of malignancy.
• Patients with renal insufficiency due to a vasculitis.
• Recipient and donor pairs with complete HLA matching.
• Patients whose condition requires continuous systemic steroid administration.
• Patients who are simultaneously participating or plan to participate in any other clinical study.
• Psychiatric or emotional problems or lack of knowledge of the German language which would invalidate the giving of Informed Consent or limit the ability of the subject to comply with study requirements.

Sponsors & Collaborators

• University Hospital Schleswig-Holstein: lead

Study Officials

• Ulrich Kunzendorf, MD

  University of Schleswig-Holstein, Campus Kiel Department of Nephrolgy

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: September 14, 2005
• First Posted: September 22, 2005
• Study Start: February 1, 2004
• Study Completion: August 1, 2005
• Last Updated: October 28, 2005

Record last verified: 2003-04